Chronic Kidney Disease Clinical Trial
Official title:
A Phase 3 Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia
Verified date | September 2022 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).
Status | Completed |
Enrollment | 334 |
Est. completion date | March 26, 2020 |
Est. primary completion date | September 13, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Subjects who were diagnosed with non-dialysis Chronic Kidney Disease and who are considered not to require renal replacement therapy during the study period - Subjects with renal anemia who have been receiving erythropoiesis stimulating agent (ESA) by subcutaneous injection and whose Hb values are considered stable. - Mean of the subject's two most recent Hb values before randomization during the Screening Period must be =10.0 g/dL and =12.0 g/dL - Either transferrin saturation = 20% or serum ferritin = 100 ng/mL - Female subject must either: Be of non-childbearing potential: - post-menopausal, or - documented surgically sterile Or, if of childbearing potential, - Agree not to try to become pregnant during the study and for 28 days after the final study drug administration - And have a negative urine pregnancy test at pre-screening - And, if heterosexually active, agree to consistently use two forms of highly effective birth control* (at least one of which must be a barrier method) starting at pre-screening and throughout the study period and continued for 28 days after the final study drug administration. - Female subject must agree not to breastfeed starting at pre-screening and throughout the study period, and continued for 28 days after the final study drug administration. - Female subject must not donate ova starting at pre-screening and throughout the study period, and continued for 28 days after the final study drug administration. - Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and continue throughout the study period, and for 12 weeks after the final study drug administration - Male subject must not donate sperm starting at pre-screening and throughout the study period and, for 12 weeks after the final study drug administration Exclusion Criteria: - Concurrent retinal neovascular lesion untreated or macular edema untreated, and patients with any condition that significantly compromises the ability to visualize the retina - Concurrent autoimmune disease with inflammation that could impact erythropoiesis - History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastro-paresis - Uncontrolled hypertension - Concurrent congestive heart failure (NYHA Class III or higher) - History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the pre-screening assessment - Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibody at the pre-screening assessment, or positive for human immunodeficiency virus (HIV) in a past test - Concurrent other form of anemia than renal anemia - History of pure red cell aplasia - Having received treatment with protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the pre-screening assessment - Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), or total bilirubin that is greater than the criteria, or previous or concurrent another serious liver disease at pre-screening assessment - Previous or current malignant tumor (no recurrence for at least 5 years is eligible.) - Having undergone red blood transfusion and/or a surgical procedure consider to promote anemia and/or ophthalmological surgery within 4 weeks before the pre-screening assessment - Having undergone a kidney transplantation - History of serious drug allergy including anaphylactic shock - Having a previous history of treatment with ASP1517 or participation in this study - Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before informed consent acquisition |
Country | Name | City | State |
---|---|---|---|
Japan | Site JP00049 | Aasahikawa | Hokkaido |
Japan | Site JP00025 | Adachi-ku | Tokyo |
Japan | Site JP00029 | Ageo | Saitama |
Japan | Site JP00022 | Amagasaki | Hyogo |
Japan | Site JP00043 | Bunkyo-ku | Tokyo |
Japan | Site JP00063 | Chiyoda-ku | Tokyo |
Japan | Site JP00047 | Fujisawa | Kanagawa |
Japan | Site JP00014 | Fukui | |
Japan | Site JP00033 | Fukuoka | |
Japan | Site JP00065 | Fukuoka | |
Japan | Site JP00037 | Hatsukaichi | Hiroshima |
Japan | Site JP00059 | Higashiosaka | Osaka |
Japan | Site JP00067 | Hino | Tokyo |
Japan | Site JP00032 | Hiroshima | |
Japan | Site JP00039 | Hiroshima | |
Japan | Site JP00052 | Hitachi | Ibaraki |
Japan | Site JP00005 | Izumisano | Osaka |
Japan | Site JP00001 | Kamakura | Kanagawa |
Japan | Site JP00035 | Kanazawa | Ishikawa |
Japan | Site JP00017 | Kasama | Ibaraki |
Japan | Site JP00009 | Kasugai | Aichi |
Japan | Site JP00008 | Kitakyusyu | Fukuoka |
Japan | Site JP00013 | Kitakyusyu | Fukuoka |
Japan | Site JP00040 | Kitakyusyu | Fukuoka |
Japan | Site JP00057 | Kitakyusyu | Fukuoka |
Japan | Site JP00028 | Koga | Ibaraki |
Japan | Site JP00004 | Koshigaya | Saitama |
Japan | Site JP00020 | Koshigaya | Saitama |
Japan | Site JP00015 | Koto-ku | Tokyo |
Japan | Site JP00050 | Kure | Hiroshima |
Japan | Site JP00042 | Kurume | Fukuoka |
Japan | Site JP00045 | Kyoto | |
Japan | Site JP00002 | Maebashi | Gunma |
Japan | Site JP00038 | Matsuyama | Ehime |
Japan | Site JP00044 | Matsuyama | Ehime |
Japan | Site JP00024 | Minato-ku | Tokyo |
Japan | Site JP00031 | Morioka | Iwate |
Japan | Site JP00006 | Musashino | Tokyo |
Japan | Site JP00018 | Nagano | |
Japan | Site JP00068 | Nagano | |
Japan | Site JP00030 | Nagoya | Aichi |
Japan | Site JP00051 | Nagoya | Aichi |
Japan | Site JP00053 | Naka | Ibaraki |
Japan | Site JP00026 | Niigata | |
Japan | Site JP00066 | Nishinomiya | Hyogo |
Japan | Site JP00034 | Oita | |
Japan | Site JP00055 | Okayama | |
Japan | Site JP00056 | Osaka | |
Japan | Site JP00061 | Osaka | |
Japan | Site JP00060 | Ota-ku | Tokyo |
Japan | Site JP00011 | Sakai | Osaka |
Japan | Site JP00003 | Sakura | Chiba |
Japan | Site JP00007 | Sapporo | Hokkaido |
Japan | Site JP00064 | Sapporo | Hokkaido |
Japan | Site JP00023 | Sashima-gun | Ibaraki |
Japan | Site JP00012 | Sendai | Miyagi |
Japan | Site JP00062 | Tachikawa | Tokyo |
Japan | Site JP00041 | Tajimi | Gifu |
Japan | Site JP00019 | Toride | Ibaraki |
Japan | Site JP00010 | Toyama | |
Japan | Site JP00021 | Toyohashi | Aichi |
Japan | Site JP00046 | Tsuchiura | Ibaraki |
Japan | Site JP00036 | Ueda | Nagano |
Japan | Site JP00069 | Yao | Osaka |
Japan | Site JP00016 | Yokohama | Kanagawa |
Japan | Site JP00048 | Yokohama | Kanagawa |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Inc | FibroGen |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in the average Hemoglobin (Hb) | Baseline and Weeks 18 to 24 | ||
Secondary | Average Hb from Week 18 to Week 24 | Up to Week 24 | ||
Secondary | Number of Participants Who Achieved the Average Hb level of 10.0 to 12.0 g/dL For Weeks 18 to 24 | Weeks 18 to 24 | ||
Secondary | Number of participants who achieve the target Hb level at each week | Up to Week 24 | ||
Secondary | Change from baseline in Hb to each post-dosing time point | Baseline and Up to Week 52 | ||
Secondary | Proportion of time points that achieve the target Hb level from Weeks 18 to 24 | Up to Week 24 | ||
Secondary | Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment | Up to Week 4 | ||
Secondary | Quality of life assessed by SF-36 | SF-36: Medical Outcomes Study 36-Item Short-Form Health Survey | Up to Week 52 | |
Secondary | Quality of life assessed by EQ-5D-5L | EQ-5D: EuroQol 5 Dimension 5 Levels | Up to Week 52 | |
Secondary | Quality of life assessed by WPAI:ANS | WPAI:ANS: Work Productivity and Activity Impairment Questionnaire: Anaemic Symptoms | Up to Week 52 | |
Secondary | Quality of life assessed by FACT-An | FACT-An: Functional Assessment of Cancer Therapy-Anemia | Up to Week 52 | |
Secondary | Average Hb from weeks 44 to 52 | Up to Week 52 | ||
Secondary | Change from baseline in the average Hb from weeks 44 to 52 | Baseline and Up to Week 52 | ||
Secondary | Number of Participants Who Achieved the Average Hb level of 10.0 to 12.0 g/dL For Weeks 44 to 52 | Weeks 44 to 52 | ||
Secondary | Number of participants who achieve the target Hb level at each week | Up to Week 52 | ||
Secondary | Proportion of time points that achieve the target Hb level from Weeks 44 to 52 | Up to Week 52 | ||
Secondary | Average Hematocrit Level | Up to Week 52 | ||
Secondary | Average Reticulocyte Level | Up to Week 52 | ||
Secondary | Average Ferrum Level | Up to Week 52 | ||
Secondary | Average Ferritin Level | Up to Week 52 | ||
Secondary | Average Transferrin Level | Up to Week 52 | ||
Secondary | Average Total Iron Binding Capacity Level | Up to Week 52 | ||
Secondary | Average Soluble Transferrin Receptor Level | Up to Week 52 | ||
Secondary | Average Soluble Transferrin Level | Up to Week 52 | ||
Secondary | Average Reticulocyte Hemoglobin Content Level | Up to Week 52 | ||
Secondary | Number of Occurence of Hospitalizations | Up to Week 52 | ||
Secondary | Duration of Hospitalization | Up to week 52 | ||
Secondary | Number of participants with abnormal Vital signs and/or adverse events related to treatment | Up to Week 52 | ||
Secondary | Safety assessed by body weight | Up to Week 52 | ||
Secondary | Safety assessed by incidence of adverse events | Up to Week 52 | ||
Secondary | Safety assessed by standard 12-lead electrocardiogram | Up to Week 52 | ||
Secondary | Safety assessed by ophthalmological examination: Fundoscopy | Up to Week 24 | ||
Secondary | Safety assessed by ophthalmological examination: optical coherence tomography | Up to Week 24 | ||
Secondary | Safety assessed by ophthalmological examination: visual acuity | Up to Week 24 | ||
Secondary | Number of participants with abnormal Laboratory values and/or adverse events related to treatment | Up to Week 52 | ||
Secondary | Plasma concentration of unchanged ASP1517 | Up to Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |